MedTrace Logo

Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin

NCT00973986 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-11-29

No results posted yet for this study

Summary

The aim of the study is to investigate the effects of CYP3A polymorphisms on the pharmacokinetics of Atorvastatin in Chinese subjects with coronary heart disease.

Conditions

Interventions

DRUG

Atorvastatin

The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.

Sponsors & Collaborators

  • Guangdong Province, Department of Science and Technology

    collaborator OTHER_GOV

  • Liuhuaqiao Hospital

    lead OTHER

Principal Investigators

  • Zhao Shujin, PhD · Guangzhou General Hospital of Guangzhou Military Command

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-12-31
Completion
2011-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00973986 on ClinicalTrials.gov